Pi Day shines a light on US math crisis as scores hit 40-year low
National Pi Day highlights declining U.S. math scores due to pandemic learning loss and AI reliance, as noted by Numerade CEO Nhon Ma.
Washington state scores slightly exceed national averages, but concerns over accountability, large classes, and reduced funding impact educational equity.
Ma stresses the need for equal opportunities and practice, with AI platforms like Numerade providing affordable tutoring alternatives.
SEATTLE - March 14 marks National Pi Day, celebrating the mathematical constant 3.14, the ratio of a circle's circumference to its diameter. While the day is often observed with pizza and pie, it also highlights the significance of math education — an area where U.S. students are struggling.
According to Nhon Ma, CEO and co-founder of Numerade, a hybrid AI STEM learning platform, math scores across the country are at a 40-year low.
"It's a stark reality," Ma said. "We're actually seeing scores plummeted in a big way."
The backstory
Experts cite multiple factors for the decline. Ma points to learning loss from the COVID-19 pandemic, along with the increasing reliance on artificial intelligence.
"Certainly, learning loss from the pandemic is a contributing factor, but then also with the rise of what's happening now with AI, you are actually getting a lot of cheating that's happening, lack of critical thinking that's developing," Ma said.
Washington state is no exception. According to the latest Nation's Report Card, last year's fourth-graders scored an average of 238 in math, just one point above the national average. In reading, eighth-graders scored 259, nearly matching the national average of 257.
What they're saying
"There is an overarching lack of accountability in terms of ensuring that every single student gets the marks and grades and they're actually learning," Ma said. "If I would have pointed in one single thing, it's a lack of accountability across these measures to hold students accountable to achievement that has not been there across the board."
Beyond test scores, classroom sizes are a growing concern, making individualized attention more difficult. Additionally, the U.S. Department of Education saw nearly a 50% budget cut under the Trump administration — something Ma fears will negatively impact educational equity.
"Now, I think what some of the biggest risk is around Title One schools and funding for lower-income students," he said. "It's going to trickle down to teacher training when it comes to STEM and Special-Ed, teachers will be less equipped and so these are items that we have to be very mindful of as it could be very disruptive."
What's next
If current trends continue, Ma predicts more students will fall behind by more than a grade level — something already happening in the Highland and Auburn school districts. A decline in STEM proficiency, he warns, could hinder future societal advancement. FOX 13 Seattle asked if it's too late to fix our education system to which Ma said, "I would say it's too late. I think what's very important is that we have to make sure that there is equal opportunity for every single student."
For students struggling with math, he emphasizes the importance of practice. While private tutors may be unaffordable for many families, Numerade's AI-powered technology offers an alternative.
"The Numerade platform walks that student through that problem in a visual format versus spoon-feeding the answer to the student," Ma said.
The Source
Information in this story comes from original reporting by FOX 13 Seattle reporter Alejandra Guzman.
Fire destroys, damages multiple Cybertrucks in Seattle lot
Bryan Kohberger defense ramps up legal maneuvers in bid to keep Idaho murders suspect off death row
Major TSA change to shorten airport security wait times, DHS says: What to know
Seattle Seahawks trade DK Metcalf to Pittsburgh Steelers
To get the best local news, weather and sports in Seattle for free, sign up for the daily FOX Seattle Newsletter.
Download the free FOX LOCAL app for mobile in the Apple App Store or Google Play Store for live Seattle news, top stories, weather updates and more local and national coverage, plus 24/7 streaming coverage from across the nation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Here's what caused the swarm of 1,350 earthquakes at WA's Mount Rainier
The Brief More than 1,350 earthquakes hit Mount Rainier between July and August. A swarm of earthquakes near a volcano can happen for several reasons. A team of scientists collected data from Rainier to determine potential hazards. MOUNT RAINIER NATIONAL PARK, Wash. - A recent swarm of more than 1,350 small earthquakes near Mount Rainier raised alarms across the Pacific Northwest this summer, but according to new findings from the U.S. Geological Survey (USGS), there's no sign the volcano is waking up – at least not in the way people might fear. Why you should care Researchers from the USGS Cascades Volcano Observatory say earthquakes near a volcano can be caused by several different factors, and identifying the source helps scientists prepare for potential hazards. To find out what triggered this summer's swarm, a team of USGS gas specialists partnered with the National Park Service for a helicopter flight over the volcano's summit. Equipped with sensitive gas detection tools, they took measurements near small steam vents, called fumaroles, located in the east and west summit craters. What they're saying "Volcanic gas sampling can help reveal the cause of earthquakes in a volcanic system, much like how blood tests help a doctor figure out what's causing a patient's symptoms," wrote the USGS. What they found suggests the quakes were likely linked to hydrothermal activity, a process where underground water is heated by the volcano and begins to circulate. While that might sound alarming, scientists say this is a common feature of active volcanoes like Rainier. The gas sensors detected small amounts of water vapor and carbon dioxide, but no traces of sulfur-based gases such as sulfur dioxide or hydrogen sulfide. These sulfur gases tend to appear when fresh magma is rising toward the surface. The absence of those gases suggests no new magma is currently on the move. So why were there so many earthquakes? The findings indicate the shaking was not caused by rising magma or an impending eruption, but likely by shifts in the volcano's shallow hydrothermal system. "The gas measurements indicate that despite over 1,350 small earthquakes happening at Rainier in July and August, the volcano's gas output has not changed much," wrote the USGS. What does this mean for Mount Rainier's current activity? Big picture view These results confirm that while Mount Rainier is still very much alive, its recent burst of seismic activity doesn't indicate anything out of the ordinary for an active volcano with an existing hydrothermal system. The Source Information in this story comes from the United States Geological Survey (USGS). MORE NEWS FROM FOX 13 SEATTLE Travis Decker WA manhunt reveals new forensic evidence amid zero leads Closures of Fred Meyer in Tacoma, WA impacting 200 employees, creates 'food desert' WA troopers make 2 arrests using plane to track down driver, motorcyclist In-N-Out Burger opens in Ridgefield, WA this week Special Forces vet exposes tactics of Montana, Washington state survivalists: 'Can't stay hidden forever' This is the best community college in WA, report says Reptile Zoo to close in Monroe after 30 years To get the best local news, weather and sports in Seattle for free, sign up for the daily FOX Seattle Newsletter. Download the free FOX LOCAL app for mobile in the Apple App Store or Google Play Store for live Seattle news, top stories, weather updates and more local and national news. Solve the daily Crossword
Yahoo
4 hours ago
- Yahoo
Why people embrace conspiracy theories: it's about community, not gullibility
Psychologists have long considered how a tendency towards irrational thinking or particular personality traits might predict peoples' interest in conspiracies. Yet these individual factors do not explain the group processes through which conspiracy theorists are extending their influence and impact. Over five years, we sought out and got to know people on the cusp of becoming conspiracy theorists. And the results of our new study show that a sense of community activism is attracting people to these ideas. Indeed, contrary to the stereotype of isolated keyboard warriors who have gone down the rabbit hole, conspiracy theorists are becoming organised, recruiting supporters, picketing vaccination centres and vandalising telecommunication and traffic infrastructures. Our research examined the growing interest in conspiracy theories and how associated activism emerges. Immersive research with conspiracy theorists is rare. But revealing our status as researchers actually allowed us to build relationships with people, who shared insights into what motivates their involvement. In particular, we spoke to people about conspiracy theories concerning 5G technology, COVID-19, 15-minute cities and low-traffic neighbourhoods. We also took part in online discussions and travelled the UK to sit in on public meetings and conferences. Ultimately, our insights revealed how people tend to follow a pathway from initial interest, to community engagement and potentially activism. Awakenings Belief in conspiracy theories is often initiated by traumatic life events. Job losses or the death of a loved one can trigger anger and suspicion towards public services, authority figures, and experts. This is especially so if people feel that the tragic or destructive events that affected them could have been averted. And these emotions can motivate a search for answers. When conspiracy theories claim to explain painful personal circumstances or wider fears over COVID-19, or climate change, people can experience 'awakenings'. These are moments of insight during which people come to believe that the causes of their problems lie with secretive groups which control society. One person we spoke to described conspiracy theories as enabling him to 'access the way the world really works… as if a light was switched on in my head and I could see things clearly'. People rarely experience their awakening in isolation. In online group chats, people discover others with similar problems. In public meetings, beliefs in various theories are boosted by interactions where people discuss their suspicions over who is to blame for particular issues. In the process, these groups feed off their common emotions, building an atmosphere of energy and excitement. The loss of traditional meeting places such as pubs and high streets, along with high levels of loneliness, may be driving people to look for new forms of connection and meaning. The people we spoke to expressed surprise at the social connections they had found through these communities. As one participant put it, 'there's a lot of support out there for people who are doing their own research… there is always someone wanting to hear more, building on the work of others, giving each other support. There's a real buzz in this community.' Do your own research Conspiracy theories don't merely offer alternative explanations for events, they are resources for communities that provide identity, purpose and belonging. These benefits may explain why it is so difficult to talk people out of their beliefs in conspiracy theories. Indeed, when conspiracy communities generate common interpretations and shared emotions, conspiracy theories can resonate powerfully, making them seem more real than they are. This effect is compounded by the way which conspiracy theories invite believers to build on ideas by 'doing their own research'. The internet serves as a vast database where conspiracy theorists can discover articles, documents and scientific reports to support their claims. And despite the questionable quality of many such sources, contributing to conspiracy theories can provide a boost to people's self esteem, making them feel like experts and heroic detectives. A key aspect of these communities is how they empower members to contribute. Yet, beyond generating more theories, conspiracy communities are becoming organised networks for protest and activism. Given that conspiracy theories raise suspicion and anger over peoples' problems, and point the blame at particular targets, we found that believers can feel compelled to take part in protests. For example, some claim that the urban planning concept of 15-minute cities is part of secretive government scheme to limit citizens' movement. Protesters against these and other efforts to improve urban environments are uniting under slogans such as 'stop the tyranny'. Who benefits? Activism based on conspiracy theories can come with serious risks. Many of those involved lose contact with family and friends. Increasingly, conspiracy activists are being charged with crimes. In 2024, an anti-vaccine conspiracy theorist was sentenced to prison for five years for encouraging violence against chief medical officer for England, Chris Witty. Moreover, when conspiracy theorists take action without tested evidence, they may misidentify targets. This can result in harm to innocent people and can undermine the very institutions needed to solve crimes. To be sure, instances of conspiracy and foul play by powerful figures and organisations do happen. You have to wonder how much energy then, is wasted fighting imaginary enemies while actual wrongdoing is overlooked. Perhaps the real winners here are the conspiracy entrepreneurs – people who capitalise on conspiracy theories by creating content that heightens peoples' suspicions about problematic events. In the process, these people build attention and fame, while peddling products and services from books, merchandise and coaching, to vitamin pills and gadgets. This article is republished from The Conversation under a Creative Commons license. Read the original article. The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.
Indianapolis Star
16 hours ago
- Indianapolis Star
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.
